<DOC>
	<DOC>NCT01414816</DOC>
	<brief_summary>To identify problems/questions about following items in the clinical practice using Betaferon 1. Unknown adverse event (especially serious adverse event) 2. Identification of adverse event occurred in the real practice 3. Factors that may affect the safety of drug 4. Factors that may affect the effectiveness of the drug</brief_summary>
	<brief_title>BetaferonÂ® Regulatory Post-Marketing Surveillance</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients with diagnosis of MS or CIS and decision taken by the physician to prescribe Betaferon Patients who have not participated in Betaferon regulatory Post Marketing Surveillance before. Exclusion criteria must be read in conjunction with local product information</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Clinical Isolated Syndrome (CIS)</keyword>
</DOC>